• HTBA is a world class producer of flavonoids and vitamin B12 in the healthcare and food industries.

Miura Partners (Miura) has signed the acquisition of HTBA (HealthTech Bioactives), a science-based global leader in the production and commercialization of natural ingredients, such as citrus flavonoids, and Europe’s leading provider of active vitamin B12 forms for the pharmaceutical, nutraceutical, food and beverage, and animal nutrition sectors.

With headquarters in Barcelona, Spain, HTBA has pioneered the development of new processes for over forty years to create high-quality, naturally derived ingredients that support the health of people and animals, all while protecting the environment.

HTBA produces ingredients at its state-of-the-art manufacturing facility in Murcia, Spain, and has an operations center located in Cincinnati, Ohio. The company sells to customers in more than 60 countries around the world.

In this new phase, Miura will drive both organic and inorganic initiatives to consolidate HTBA as a leading platform for natural ingredients in the health and food sectors.

This marks the third investment of Miura Fund IV, which held its final close in 2024 with a size of €475 million.

Jordi Alegre, Managing Partner at Miura Partners:

“We are very pleased with our investment in HTBA, a leader in the strategic natural ingredients sector for the pharmaceutical and nutrition industries, with a strong track record in innovation, growth and sustainability. This investment aligns well with our mid-market buy-outs strategy, focusing on industry-leading companies with solid business models, strong growth potential and a top-tier management team.

Alexandre Valls-Coma, Chief Executive Officer of HTBA:

“This new chapter in the company’s history represents a significant progress and the consolidation of our growth strategy based on innovation and sustainability. We remain focused on providing solutions that enhance the health and well-being of both people and animals, as a global leader in the manufacturing and distribution of flavonoids and active forms of vitamin B12”.

Miura was advised by Houlihan Lokey (M&A), Linklaters (Legal), KPMG (Due Diligence) and Bain & Company (Commercial Due Diligence). The transaction is pending approval of the Spanish Regulator.

About HTBA

With nearly 50 years of history, HTBA is currently a global leader in the manufacturing and distribution of flavonoids and active forms of vitamin B12. The company is at the forefront of research, development, and production of high-value-added ingredients, harnessing the power of nature while ensuring sustainability for future generations.

About Miura Partners

Miura Partners is a purpose-driven Private Equity firm. With offices in Barcelona and Madrid, the firm specializes in investing in small and medium-sized family-owned and entrepreneurial companies. Miura provides attractive growth and innovation plans with a clear focus on sustainability and internationalization.

The firm currently manages assets exceeding €1.5bn and has completed more than 80 investments worth in excess of €4bn since its inception in 2008.